Show simple item record

dc.contributor.authorKaaijk, Patricia
dc.contributor.authorEmmelot, Maarten E
dc.contributor.authorMeiring, Hugo D
dc.contributor.authorvan Els, Cécile A C M
dc.contributor.authorde Wit, Jelle
dc.date.accessioned2021-07-15T20:19:46Z
dc.date.available2021-07-15T20:19:46Z
dc.date.issued2021-07-01
dc.identifier.pmid34211021
dc.identifier.doi10.1038/s41598-021-92926-1
dc.identifier.urihttp://hdl.handle.net/10029/625100
dc.description.abstractMumps is nowadays re-emerging despite vaccination. The contribution of T cell immunity to protection against mumps has not been clearly defined. Previously, we described a set of 41 peptides that were eluted from human leukocyte antigen (HLA) class I molecules of mumps virus (MuV)-infected cells. Here, we confirmed immunogenicity of five novel HLA-B*07:02- and HLA-A*01:01-restricted MuV T cell epitopes from this set of peptides. High frequencies of T cells against these five MuV epitopes could be detected ex vivo in all tested mumps patients. Moreover, these epitope-specific T cells derived from mumps patients displayed strong cytotoxic activity. In contrast, only marginal T cell responses against these novel MuV epitopes could be detected in recently vaccinated persons, corroborating earlier findings. Identifying which MuV epitopes are dominantly targeted in the mumps-specific CD8+ T- response is an important step towards better understanding in the discrepancies between natural infection or vaccination-induced cell-mediated immune protection.en_US
dc.language.isoenen_US
dc.titleNovel mumps virus epitopes reveal robust cytotoxic T cell responses after natural infection but not after vaccination.en_US
dc.typeArticleen_US
dc.identifier.eissn2045-2322
dc.identifier.journalSci Rep 2021; 11(1):13664en_US
dc.source.journaltitleScientific reports
dc.source.volume11
dc.source.issue1
dc.source.beginpage13664
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record